
ANRO Stock Forecast & Price Target
ANRO Analyst Ratings
Bulls say
Alto Neuroscience Inc. is advancing its clinical-stage pipeline with a strong focus on targeting depressive disorders and schizophrenia using brain-based biomarkers, which positions the company to potentially redefine treatment options in psychiatry. The recent updates highlight a resolute commitment to mitigating biases in its clinical designs, particularly in the ALTO-100 Phase 2b study, which, if successful, could enhance the overall efficacy and safety profile of its treatments. Additionally, the increasing valuation discount rate suggests a cautious yet optimistic outlook on the future performance of the company's stock amidst evolving clinical outcomes and strategic positioning.
Bears say
Alto Neuroscience Inc. experienced a significant setback with the ALTO-100 trial in major depressive disorder (MDD), leading to diminished confidence in its future MDD programs despite extensive efforts to ensure successful study execution. The disappointing results from the Phase 2b study, especially in a population targeted by cognitive biomarkers, raise concerns about the effectiveness of the company's treatment strategies and overall prospects for innovation in the sector. Additionally, there are potential risks associated with access to capital markets, which, if limited, could further adversely affect the company's financial stability and stock performance.
This aggregate rating is based on analysts' research of Alto Neuroscience Inc and is not a guaranteed prediction by Public.com or investment advice.
ANRO Analyst Forecast & Price Prediction
Start investing in ANRO
Order type
Buy in
Order amount
Est. shares
0 shares